A blood fat index tracked some heart outcomes, but clinical usefulness remains uncertain
An umbrella review found links between the Atherogenic Index of Plasma and several cardiovascular outcomes, alongside important results that were not statistically significant.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Higher values of the Atherogenic Index of Plasma, or AIP, were associated with heart attacks and cardiovascular deaths among people with coronary artery disease. Associations with overall mortality and stroke in that group were not statistically significant. These patterns do not show that AIP causes disease or that using it improves clinical decisions.
The abstract does not specify the AIP thresholds or increments behind its comparisons, follow-up periods, or number of contributing studies. These omissions limit interpretation of the associations and the proposed screening role.
Different outcomes gave different answers
The review linked AIP with several cardiovascular and metabolic outcomes, but the pattern was not uniform. Non-alcoholic fatty liver disease also showed no statistically significant association, reinforcing the need to keep individual outcomes separate.
What a biomarker link leaves open
The authors propose AIP as a possible tool for risk assessment and screening. The associations summarized here do not establish how much it adds to existing assessment or whether its use changes patient outcomes.
The original publication
Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses.
Rashidian P, Mirchandani M, Somu KP et al.
BMC Cardiovasc Disord · 2025
- PubMed ID
- 41382002
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.